Serum Soluble Interleukin 2 Receptor Levels in Erythrodermic Cutaneous T-Cell Lymphoma Correlate With Response to Photopheresis-Based Treatment

Goldman, Barry

doi:10.1001/archderm.1993.01680300094015

Cited by 9 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other investigators have published that high serum levels of LD indicate an unfavourable response to ECP 13–15 . In our study we found only slightly elevated mean values of LD and, indeed, the responding group was the higher one.…”

Section: Discussionsupporting

confidence: 47%

See 1 more Smart Citation

Extracorporeal photochemotherapy in patients with cutaneous T‐cell lymphoma: is clinical response predictable?

Rao

Ryggen²,

Aarhaug

et al. 2006

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 47%

“…The level of lactate dehydrogenase (LD) is also used clinically as a prognostic factor to characterize the growth and invasive potential of tumours 12 . Studies have indicated that high serum levels of sIL‐2R and LD correlate with a poor therapy response and prognosis 13–15 …”

mentioning

confidence: 99%

Extracorporeal photochemotherapy in patients with cutaneous T‐cell lymphoma: is clinical response predictable?

Rao

Ryggen²,

Aarhaug

et al. 2006

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…TCR β F1 + phenotype does not fit into γδ T-cell lymphoma neither. [5][6][7] In our case, sIL-2R increased when she developed nodular cutaneous lesions although it was normal during her initial visit. In most cases of this category, however, aberrant CD4 + T-cell phenotypes with loss of pan-T-cell antigens are seen.…”

Section: Discussionmentioning

confidence: 55%

Primary cutaneous T‐cell lymphoma, unspecified, exhibiting an aggressive clinical course and a cytotoxic phenotype

2008

View full text Add to dashboard Cite

“…With a chronic disease like CTCL, surrogate markers are a necessity. Noncutaneous surrogate markers have been proposed, such as serum levels of soluble interleukin (IL)‐2 receptor3 and eosinophil count 4. However, each of these has to be grounded in its correlation with skin involvement, making the recording of the examination of the patient the crucial event in monitoring disease activity.…”

Section: Various Findings Associated With Outcome In Cutaneous T Cellmentioning

confidence: 99%

Clinical Trials and Efficacy Assessment in the Therapy of Cutaneous T Cell Lymphoma

Heald

2001

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The ability of clinical trials to measure cutaneous T cell lymphoma (CTCL) has allowed physicians and regulatory reviewers to assess the response of the disease to experimental therapies. The goals of therapy are remission, palliation, and improvement of survival. Given the chronic nature of the disease, surrogate markers for survival are used in clinical trials. The surrogate markers and the validity of the surrogate markers used to date will be compared and contrasted. Tumor burden measurements by way of skin scoring are the parameters most commonly used to assess the response to therapy. Skin scoring systems have used global mapping, severity recording, or target lesions to assess any change in response to an intervention. The advantages and limitations of global and focal scoring are presented, along with examples of skin scoring systems for the five most recently completed trials for CTCL. Measures of palliation are performed via questionnaires. General and CTCL‐specific questionnaires have been developed that assess both discrete and global manifestations of the disease. Those measures of palliation that have been shown to correlate with skin scoring are presented for inclusion into future studies. In addition, study terms such as relapse and freedom from relapse can now be defined with reproducible molecular techniques. Every stage of CTCL warrants further clinical trials, and guidelines for future investigations are proposed.

show abstract

Serum Soluble Interleukin 2 Receptor Levels in Erythrodermic Cutaneous T-Cell Lymphoma Correlate With Response to Photopheresis-Based Treatment

Cited by 9 publications

References 6 publications

Extracorporeal photochemotherapy in patients with cutaneous T‐cell lymphoma: is clinical response predictable?

Extracorporeal photochemotherapy in patients with cutaneous T‐cell lymphoma: is clinical response predictable?

Primary cutaneous T‐cell lymphoma, unspecified, exhibiting an aggressive clinical course and a cytotoxic phenotype

Clinical Trials and Efficacy Assessment in the Therapy of Cutaneous T Cell Lymphoma

Contact Info

Product

Resources

About